J i Super Q in
J i Super Q in
This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.
Gastric Carcinoma
In addition to routine diagnosis and treatment, no additional intervention measures were taken.
In the 6th edition of the Japanese Gastric Cancer Treatment Guidelines; during proximal gastrectomy, D2 lymphadenectomy includes nodes No. 1, No. 2, No. 3a, No. 4sa, No. 4sb, No. 7, No. 8a, No. 9, No. 11p, and No. 11d. When performing D2 surgery for proximal gastric cancer, the dissection typically includes No. 3a (Lymph nodes along the branches of the left gastric artery, including those below the cardia branch) and No. 7 (distributed along the left gastric artery from its root to the bifurcation of the ascending branch), while not including the No. 5 group nodes (located in the upper region of the pylorus between the root of the right gastric artery and the first branch of the gastric wall). In D2 lymphadenectomy plus complete mesogastric excision (CME) for proximal gastric cancer, a complete resection of the left gastric mesentery is performed without removing the right gastric mesentery. However, clinical observations have shown that there may be a fusion between the left and right gastric mesenteries. Merely excising the left gastric mesentery could potentially lead to tumor residue or recurrence in the right mesentery. This study aims to investigate tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery following D2+CME surgery for proximal gastric cancer, intending to provide evidence-based medical insights for standardizing lymph node clearance in gastric cancer.
| Study Type : | OBSERVATIONAL |
| Estimated Enrollment : | 100 participants |
| Official Title : | Tumor Deposit At the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients with Gastric Cancer Who Received Proximal Gastrectomy with D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: a Prospective Observational Study |
| Actual Study Start Date : | 2025-05-01 |
| Estimated Primary Completion Date : | 2027-12-31 |
| Estimated Study Completion Date : | 2027-12-31 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 85 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000